Compare Sony Group Corp (SONY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs Viatris Inc — how do they compare? Sony Group Corp trades at $21.02 (market cap $125.96B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Sony Group Corp is far larger — about 6.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| SONY | VTRS | |
|---|---|---|
Market Cap | $125.96B | $19.79B |
Sector | Technology | Health |
52-Week High | $30.26 | $17.39 |
52-Week Low | $19.32 | $8.74 |
Enterprise Value | $122.45B | $32.00B |
Dividend Yield | 0.75% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony trades at $21.02, down 0.47% on the day. The stock shows a bullish technical signal with strong moving average alignment, though oscillators are neutral. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Revenue for 2025 was $12.96 trillion with a net income of $1.14 trillion, though 2026 projections indicate a net loss. Analyst sentiment is positive with 11 buy ratings and no sell recommendations.
The outlook for Sony is mixed; strong cash flow and a solid balance sheet support growth in entertainment and AI investments, but the shift away from physical media and projected 2026 losses pose risks. Investor sentiment remains cautiously optimistic given the bullish analyst consensus and strategic initiatives.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
